Seres Therapeutics, Inc. (MCRB)
NASDAQ: MCRB · Real-Time Price · USD
5.33
+0.15 (2.90%)
At close: Jul 17, 2026, 4:00 PM EDT
5.60
+0.27 (5.07%)
Pre-market: Jul 20, 2026, 4:06 AM EDT
Seres Therapeutics Stock Forecast
Stock Price Forecast
According to 2 analysts polled by S&P Global, Seres Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $17. The average 1-year stock price forecast is 218.95% higher than the current stock price, while the lowest is $12 (+125.14%) and the highest is $22 (+312.76%).
Price Target: $17 (+218.95%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Seres Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Feb '26 | Mar '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 1 | 1 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $22 | Buy | Maintains | $22 | +312.76% | Jul 9, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $12 | Buy | Reiterates | $12 | +125.14% | Jul 8, 2026 |
| Piper Sandler | Piper Sandler | Hold Maintains $20 | Hold | Maintains | $20 | +275.23% | Feb 13, 2026 |
Financial Forecast
Revenue This Year
12.86M
from 789.00K
Increased by 1,529.66%
Revenue Next Year
358.00K
from 12.86M
Decreased by -97.22%
EPS This Year
-7.52
from 0.64
EPS Next Year
-6.58
from -7.52
EPS and Forward PE are based on non-GAAP adjusted numbers.